These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27655335)

  • 21. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and properties of biologically active fluorescent heparins.
    Nagasawa K; Uchiyama H
    Biochim Biophys Acta; 1978 Dec; 544(2):430-40. PubMed ID: 719009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
    J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
    Castro-López V; Harris LF; O'Donnell JS; Killard AJ
    Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation of thrombin activatable fibrinolytic inhibitor by low molecular weight heparins. Pharmacologic implications.
    Florian-Kujawski M; Hoppensteadt D; Maddineni J; Ziegler H; Fareed J
    Int Angiol; 2004 Dec; 23(4):346-54. PubMed ID: 15767980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-molecular-weight heparins for the treatment of deep-vein thrombosis.
    Cziraky MJ; Spinler SA
    Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of low molecular weight heparins.
    Bara L; Samama M
    Acta Chir Scand Suppl; 1990; 556():57-61. PubMed ID: 1963018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An improved heparin assay which is insensitive to platelet factor 4.
    Fickenscher K; Buckler U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):873-8. PubMed ID: 2483705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells.
    Martinez-Sales V; Vila V; Réganon E; Oms JG; Aznar J
    Haematologica; 2003 Jun; 88(6):694-9. PubMed ID: 12801846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.
    Bjornsson TD; Schneider DE; Hecht AR
    J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
    Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
    Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection and neutralisation of heparin by a fluorescent ruthenium compound.
    Szelke H; Harenberg J; Krämer R
    Thromb Haemost; 2009 Nov; 102(5):859-64. PubMed ID: 19888520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis.
    Rosenberg RD
    Fed Proc; 1985 Feb; 44(2):404-9. PubMed ID: 3155697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.